How many drugs treat Hypocalcemia?

Drug Landscape tracks 10 marketed treatments for Hypocalcemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hypocalcemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hypocalcemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypocalcemia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypocalcemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Infuvite Adult	Colecalciferol	Novartis	Vitamin D	Vitamin D3 receptor	2000-01-01
Prepopik	MAGNESIUM OXIDE	Baxter	magnesium oxide		1982-01-01
Phoslo	CALCIUM ACETATE	Fresenius Medcl Care	calcium acetate		1982-01-01
Calcijex	CALCITRIOL	Esjay Pharma	Vitamin D3 Analog [EPC]	Vitamin D3 receptor	1978-01-01
Calcium Gluceptate	calcium glucoheptonate	Abbott	calcium glucoheptonate		1972-01-01
Plegisol In Plastic Container	CALCIUM CHLORIDE	Pfizer	calcium chloride		1971-01-01
Drisdol	ERGOCALCIFEROL	Esjay Pharma	Provitamin D2 Compound [EPC]	25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	1941-01-01
Tums	calcium carbonate	Generic (multiple manufacturers)	Antacid, Calcium supplement	Gastric acid (direct neutralization)	1930-01-01
Rocaltrol	Rocaltrol	Shandong University		Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D-binding protein
Phylloquinone	Phylloquinone	Guy's and St Thomas' NHS Foundation Trust		Alpha-synuclein

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 12 drugs in Hypocalcemia
Esjay Pharma · 2 drugs in Hypocalcemia
Baxter · 1 drug in Hypocalcemia
Department of Medical Services Ministry of Public Health of Thailand · 1 drug in Hypocalcemia
Fresenius Medcl Care · 1 drug in Hypocalcemia
Generic (multiple manufacturers) · 1 drug in Hypocalcemia
Guy's and St Thomas' NHS Foundation Trust · 1 drug in Hypocalcemia
Instituto Mexicano del Seguro Social · 1 drug in Hypocalcemia
Novartis · 1 drug in Hypocalcemia
Pfizer · 1 drug in Hypocalcemia
Shandong University · 1 drug in Hypocalcemia
Abbott · 1 drug in Hypocalcemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypocalcemia:

Cite this brief

Drug Landscape (2026). Hypocalcemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypocalcemia. Accessed 2026-06-10.

Hypocalcemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing